Takeda PharmaceuticalLtd ADR (TAK) - Stock & Dividends

Exchange: USA Stocks • Country: Japan • Currency: USD • Type: Common Stock • ISIN: US8740602052

Gastroenterology, Rare Diseases, Plasma Therapies, Immunology, Oncology, Neuroscience

Takeda Pharmaceutical Company Limited is a global leader in the pharmaceutical industry, dedicated to improving people's lives through innovative medicines and therapies. With a rich history dating back to 1781, the company has evolved into a research-driven organization, focused on discovering and developing novel treatments for various diseases.

The company's portfolio includes a wide range of pharmaceutical products, categorized into several therapeutic areas, such as gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Its product lineup boasts a diverse range of brands, including Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, and many more, which are marketed globally to address unmet medical needs.

Takeda has established a robust network of partnerships and collaborations with various biotech companies, research institutions, and academia, aimed at accelerating innovation and advancing medical research. Its collaborations include agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada, among others, to develop new treatments and technologies.

The company's research and development efforts are focused on identifying novel targets and developing innovative therapies, leveraging cutting-edge technologies and platforms. Its research collaborations with institutions like Neurocrine Biosciences, Seagen Inc., and the Center for iPS Cell Research Application, Kyoto University (CiRA), demonstrate its commitment to advancing scientific knowledge and improving patient outcomes.

Headquartered in Tokyo, Japan, Takeda Pharmaceutical Company Limited is a global organization with a strong presence in international markets. Its website, https://www.takeda.com, provides detailed information on its products, research initiatives, and corporate social responsibility initiatives.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Takeda PharmaceuticalLtd ADR (TAK) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Takeda PharmaceuticalLtd ADR (TAK) - Stock & Dividends

TAK Stock Overview

Market Cap in USD 41,464m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2008-10-27

TAK Stock Ratings

Growth 5y -19.2
Fundamental 8.69
Dividend 5.37
Rel. Performance vs Sector -2.82
Analysts 4.50/5
Fair Price Momentum 11.90 USD
Fair Price DCF 2004.53 USD

TAK Dividends

Yield 12m 4.73%
Yield on Cost 5y 4.54%
Dividends CAGR 5y -3.58%
Payout Consistency 91.8%

TAK Growth Ratios

Growth 12m -15.15%
Growth Correlation 12m -55%
Growth Correlation 3m -42%
CAGR 5y -0.83%
CAGR/Mean DD 5y -0.06
Sharpe Ratio 12m -1.19
Alpha vs SP500 12m -31.82
Beta vs SP500 5y weekly 0.58
ValueRay RSI 36.51
Volatility GJR Garch 1y 17.26%
Price / SMA 50 -1.36%
Price / SMA 200 -6.29%
Current Volume 1071.5k
Average Volume 20d 1337.8k

External Links for TAK Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of TAK stocks?
As of June 15, 2024, the stock is trading at USD 13.10 with a total of 1,071,511 shares traded.
Over the past week, the price has changed by -2.75%, over one month by -2.60%, over three months by -6.70% and over the past year by -15.15%.
What are the forecast for TAK stock price target?
According to ValueRays Forecast Model, TAK Takeda PharmaceuticalLtd ADR will be worth about 12.9 in June 2025. The stock is currently trading at 13.10. This means that the stock has a potential downside of -1.83%.
Issuer Forecast Upside
Wallstreet Target Price 18.1 38.4
Analysts Target Price 19.1 46.0
ValueRay Target Price 12.9 -1.83